BioSymetrics

[Not Yet Scheduled]
BioSymetrics is an AI-powered, phenomics-driven drug discovery company with a mission to advance precision medicines for patients in need of a better standard of care.

90 percent of clinical trials fail before a drug can make it to patients. Data is siloed, the process is inefficient, and biology is inherently complex leading to a lack of clinical translation.

To better address this complexity, BioSymetrics takes a phenomics-driven approach to drug discovery. We integrate longitudinal, real-world patient and experimental data, using machine learning, to translate human biology into medicines. We partner with clinical, genomic and pharma leaders to advance our drug discovery programs, including Janssen, Sema4, Northwell Health, and Pfizer. We are currently advancing programs in cardiovascular, rare and neurological diseases where we are seeking potential partners.

We are remote-first and have assembled a high-caliber team with prior experience in AI in the bio and tech sectors.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
BIOS-001 for atherosclerosis
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Strategy Officer and Head of Drug Discovery
BioSymetrics